Intravenous immunoglobulin treatment in hematological diseases

10.1016/0955-3886(92)90137-6

Schwartz SA., 1992, Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes, Clin Rev Allergy, 10, 1, 10.1007/BF02914366

10.1111/j.1365-2796.1993.tb00720.x

Blanchette VS, 1992, Role of intravenous imunoglobulin G in autoimmune hematologic disorders, Semin Hematol, 29, 72

10.1016/0268-960X(92)90012-F

10.1001/jama.273.23.1865

The European Agency for the Evaluation of Medicinal Products., 1996, Guidelines to assess efficacy and safety of normal intravenous immunoglobulin products for marketing authorisations

10.5694/j.1326-5377.1993.tb137790.x

10.1016/S0140-6736(85)90400-3

10.1016/S0022-3476(05)80400-7

10.3109/08880019309029508

10.1159/000204392

10.1016/S0140-6736(94)92205-5

10.1016/0002-9343(94)90048-5

10.1016/S0022-3476(05)82024-4

10.1111/j.1651-2227.1996.tb14183.x

Berchtold P., 1989, Therapy of chronic idiopathic thrombocytopenic purpura in adults, Blood, 74, 2309, 10.1182/blood.V74.7.2309.2309

10.1111/j.1423-0410.1987.tb03029.x

10.1002/ajh.2830250306

10.1016/0002-9343(87)90546-8

10.1182/blood.V82.5.1415.1415

10.1002/ajh.2830330306

10.3109/09537109309013206

10.1097/00043426-198406020-00008

10.1097/00043426-198424000-00001

Belluci S., 1988, Low doses v. conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults, Blood, 71, 1165, 10.1182/blood.V71.4.1165.1165

Mazzucconi MG, 1985, Treatment of idiopathic thrombocytopenic purpura (ITP): results of a multicentric protocol, Haematologica, 70, 329

10.1159/000204474

10.1007/BF00451950

10.1111/j.1365-2257.1988.tb00021.x

Rodeghiero F., 1992, A follow‐up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high‐dose immunoglobulins and anti‐D immunoglobulins, Haematologica, 77, 248

10.1136/adc.67.8.1056

10.1182/blood.V88.1.3.3

10.1111/j.1471-0528.1993.tb15230.x

10.1016/S0002-9378(97)80043-9

10.1002/ajh.2830180406

10.1016/0002-9378(90)90675-W

10.1111/j.1471-0528.1990.tb02443.x

10.1007/BF00320267

10.1016/0002-9343(89)90268-4

10.1046/j.1537-2995.1994.34994378275.x

10.1080/1120009X.1990.11739050

Oksenhendler E., 1990, HIV‐related thrombocytopenia, Immunodefic Rev, 2, 221

10.7326/0003-4819-109-9-718

10.1001/archinte.148.3.695

10.1007/BF00918802

10.1016/S0002-9378(96)70582-3

10.1002/(SICI)1520-6661(199609/10)5:5<281::AID-MFM6>3.0.CO;2-D

10.1016/0140-6736(92)93044-N

10.1016/0140-6736(92)92137-5

Kaplan C., 1988, Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets, Blood, 72, 340, 10.1182/blood.V72.1.340.340

10.1055/s-0038-1648202

10.1111/j.1423-0410.1993.tb02144.x

10.1182/blood.V75.1.313.313

10.1002/ajh.2830380104

10.1046/j.1537-2995.1987.27387235630.x

10.1007/BF00319544

10.1002/ajh.2830210305

10.1111/j.1600-0609.1985.tb00767.x

10.1111/j.1423-0410.1986.tb01967.x

Collins PW, 1992, Treatment modalities of autoimmune blood disorders, Semin Hematol, 29, 64

10.1002/ajh.2830440404

Ballester OF, 1992, Pure red cell aplasia: treatment with intravenous immunoglobulin concentrate, Semin Hematol, 29, 106

10.1111/j.1365-2141.1983.tb01260.x

10.7326/0003-4819-113-12-926

10.1097/00007890-199310000-00011

10.1007/BF02076698

10.1056/NEJM198810063191403

Griffiths H., 1989, Crossover study of immunoglobulin replacement therapy in patients with low‐grade‐B‐cell tumors, Blood, 73, 366, 10.1182/blood.V73.2.366.366

10.1111/j.1365-2257.1995.tb00322.x

Molica S., 1996, Prophylaxis against infections with low‐dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study, Haematologica, 81, 121

10.1111/j.1365-2141.1994.tb05002.x

Schedel I., 1986, Clinical Use of Intravenous Immunoglobulins, 123

10.1016/S0140-6736(94)90180-5

10.1016/S0002-9343(95)00043-7

Messori A., 1994, Efficacy of hyperimmune anti‐cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta‐analysis, Bone Marrow Transplant, 13, 163

10.7326/0003-4819-106-1-12

10.1056/NEJM199009133231103

Winston DJ, 1993, Intravenous immunoglobulin and CMV‐seronegative blood products for prevention of CMV infection and disease in bone marrow tranplants recipients, Bone Marrow Trans, 12, 283

Guglielmo BJ, 1994, Immune globulin therapy in allogeneic bone marrow transplant: a critical review, Bone Marrow Trans, 13, 499

Sullivan KM, 1996, A controlled trial of long‐term administration of intravenous immunoglobulin to prevent late infection and chronic graft‐vs.‐host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery, Biol Blood Marrow Trans, 2, 44

10.1056/NEJM198604173141602

Miller WJ, 1991, Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening, Bone Marrow Trans, 7, 227

10.7326/0003-4819-118-3-199302010-00003

10.7326/0003-4819-118-3-199302010-00004

10.1016/S0140-6736(83)92248-1

Lundren G., 1985, Acyclovir prophylaxis in bone marrow transplant recipients, Scand J Infect Dis, 47, 137

10.1038/bjc.1989.88

10.1016/S0140-6736(94)91835-X

10.7326/0003-4819-120-2-199401150-00008

10.1111/j.1365-2141.1984.tb04004.x

10.1046/j.1365-2141.1996.d01-1880.x

Dunkel IJ, 1993, New developments in the treatment of neutropenia, Am J Dis Child, 147, 994

10.1016/S0272-6386(12)80888-2

10.1111/j.1365-2141.1995.tb03302.x

10.1111/j.1423-0410.1994.tb00324.x

10.1111/j.1423-0410.1991.tb00944.x

10.1016/S0022-3476(05)82551-X

10.1177/030006059502300406

10.1515/jpme.1995.23.6.443

10.1016/S0140-6736(94)90661-0

10.1136/adc.71.3.251

10.1056/NEJM199107113250202

10.1136/jnnp.60.4.359

Gimesi A., 1992, Immunoglobulin prophylaxis during intensive treatment of acute lymphoblastic leukemia in children, Acta Paediatr Hung, 32, 115

10.7326/0003-4819-118-12-199306150-00004